United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

syner-med (pharmaceutical products) ltd -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

syner-med (pharmaceutical products) ltd -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

syner-med (pharmaceutical products) ltd -

Israel - English - Ministry of Health

teva israel ltd - acetylsalicylic acid - tablets enteric coated - acetylsalicylic acid 100 mg - acetylsalicylic acid - the primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - acetylsalicylic acid - tablets enteric coated - acetylsalicylic acid 100 mg - acetylsalicylic acid - acetylsalicylic acid - the primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - acetylsalicylic acid - tablets enteric coated - acetylsalicylic acid 100 mg - acetylsalicylic acid - acetylsalicylic acid - the primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium, quantity: 20.68 mg (equivalent: atorvastatin, qty 20 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; hyprolose; pregelatinised maize starch; magnesium stearate; activated attapulgite; titanium dioxide; lactose monohydrate; hypromellose; macrogol 4000 - as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium, quantity: 41.36 mg (equivalent: atorvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; activated attapulgite; pregelatinised maize starch; microcrystalline cellulose; magnesium stearate; hyprolose; lactose monohydrate; titanium dioxide; hypromellose; macrogol 4000 - as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium, quantity: 10.34 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium stearate; activated attapulgite; microcrystalline cellulose; pregelatinised maize starch; colloidal anhydrous silica; hyprolose; titanium dioxide; lactose monohydrate; hypromellose; macrogol 4000 - as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium, quantity: 82.72 mg (equivalent: atorvastatin, qty 80 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; pregelatinised maize starch; hyprolose; activated attapulgite; colloidal anhydrous silica; titanium dioxide; lactose monohydrate; hypromellose; macrogol 4000 - as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.